News
![microphones](https://pharmaphorum.com/wp-content/uploads/2022/07/microphones.jpg)
VistaGen's horizons may shrink after clinical trial setback
Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD)